Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria

Patent metadata

Field	Value
Publication number	US-9731010-B2
Application number	US-201514641571-A
Country	US
Kind code	B2
Filing date	Mar 9, 2015
Priority date	Jan 5, 2010
Publication date	Aug 15, 2017
Grant date	Aug 15, 2017

Abstract

The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of, gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.

First claim

What is claimed is:

1. A composition comprising one or more gram-positive bacteria cell wall or cell membrane disrupter and one or more gram-positive cell wall or cell membrane target inhibiting agent wherein the composition is capable of disrupting the cell wall such that the cell wall or cell membrane target is rendered exposed or accessible and sensitive to the target inhibiting agent, wherein the cell wall or cell membrane target is inaccessible, relatively insensitive, or less sensitive to the target inhibiting agent in the absence of the cell wall disrupting agent, wherein the composition is therapeutically effective to reduce bacterial cell growth, virulence or infection, and wherein the disrupter alone at the composition concentration is not effective in significantly reducing bacterial cell growth, virulence or infection.

2. The composition of claim 1 wherein the disrupter is selected from the group of antibiotics, anti-microbial peptides, polycationic peptides, cell wall degrading enzymes, and catalytic antibodies.

3. The composition of claim 1 wherein the gram-positive bacteria is selected from Actinomyces, Bacillus, Listeria, Lactococcus, Staphylococcus, Streptococcus, Enterococcus, Mycobacterium, Corynebacterium , and Clostridium.

4. The composition of claim 1 wherein the cell wall or cell membrane target is sortase.

5. The composition of claim 1 wherein the target inhibiting agent is selected from an antibody or antigen binding fragment thereof, a ligand, a bioactive peptide and an enzyme.

6. The composition of claim 1 wherein the gram-positive bacteria is antibiotic resistant.

7. The composition of claim 6 wherein the gram-positive bacteria is antibiotic resistant Staphylococcus.

8. The composition of claim 1 wherein the disrupter is an antibiotic that inhibits cell wall synthesis or cell membrane function.

9. The composition of claim 1 wherein the cell wall disrupting agent is an antibiotic and is selected from a glycopeptide, penicillin, cephalosporin, polypeptide/lipopeptide, or carbapanem antibiotic.

10. The composition of claim 1 wherein the cell wall disrupting agent is an antibiotic and is a beta-lactam antibiotic.

11. The composition of claim 1 wherein the cell wall disrupting agent is a cell wall degrading enzyme.

12. The composition of claim 1 wherein the cell wall or cell membrane target is a penicillin binding protein.

13. The composition of claim 1 wherein the target inhibiting agent is a cell wall or cell membrane target inhibiting antibody or antigen binding fragment thereof.

14. The composition of claim 1 wherein the composition is a pharmaceutical composition further comprising a suitable vehicle, carrier, or diluent.

15. The composition of claim 1 wherein the target inhibiting agent is a cell membrane target antibody and the disrupter is an antibiotic in a sub-MIC dose.

Assignees

• Nowinski Robert C
• Fischetti Vincent A
• Raz Assaf
• Univ Rockefeller
• Contrafect Corp

Inventors

• Nowinski Robert C
• Fischetti Vincent A
• Raz Assaf

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61K31/545

  Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine} · CPC title

• C12N9/52

  derived from bacteria {or Archaea} · CPC title

• A61K38/02

  Peptides of undefined number of amino acids; Derivatives thereof · CPC title

• G01N2500/02

  Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor) · CPC title